Using the combination of anti-PD-L1 antibody, atezolizumab, plus the anti-vascular endothelial growth factor antibody, bevacizumab, as an example, we discussed the limitations of this first-line treatment for advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.